Alps Advisors Inc. Acquires 1,624 Shares of Spark Therapeutics, Inc. (ONCE)

Alps Advisors Inc. raised its stake in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 6.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 28,097 shares of the biotechnology company’s stock after buying an additional 1,624 shares during the period. Alps Advisors Inc. owned approximately 0.09% of Spark Therapeutics worth $1,679,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in ONCE. Principal Financial Group Inc. boosted its stake in shares of Spark Therapeutics by 0.3% in the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock valued at $2,067,000 after buying an additional 122 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Spark Therapeutics by 2.5% in the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock valued at $923,000 after buying an additional 414 shares in the last quarter. KCG Holdings Inc. boosted its stake in shares of Spark Therapeutics by 9.4% in the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 538 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Spark Therapeutics by 1.9% in the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after buying an additional 650 shares in the last quarter. Finally, American International Group Inc. boosted its stake in shares of Spark Therapeutics by 17.4% in the first quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock valued at $618,000 after buying an additional 1,714 shares in the last quarter. Hedge funds and other institutional investors own 87.30% of the company’s stock.

Shares of Spark Therapeutics, Inc. (NASDAQ ONCE) opened at 76.05 on Friday. Spark Therapeutics, Inc. has a 52-week low of $35.07 and a 52-week high of $80.89. The company has a 50-day moving average of $69.05 and a 200-day moving average of $60.41. The stock’s market capitalization is $2.38 billion.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. During the same period last year, the firm earned ($1.04) earnings per share. Spark Therapeutics’s revenue for the quarter was up 14.7% on a year-over-year basis. Equities research analysts anticipate that Spark Therapeutics, Inc. will post ($7.79) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/18/alps-advisors-inc-acquires-1624-shares-of-spark-therapeutics-inc-once.html.

Several brokerages have recently issued reports on ONCE. Jefferies Group LLC restated a “buy” rating and set a $95.00 target price (up from $85.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Evercore ISI began coverage on shares of Spark Therapeutics in a research report on Wednesday. They set an “in-line” rating and a $83.00 target price on the stock. Zacks Investment Research upgraded shares of Spark Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 19th. BidaskClub upgraded shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Wedbush restated an “underperform” rating and set a $28.00 target price on shares of Spark Therapeutics in a research report on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the stock. Spark Therapeutics currently has an average rating of “Buy” and a consensus target price of $82.32.

In other Spark Therapeutics news, General Counsel Barge Joseph La sold 5,000 shares of Spark Therapeutics stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $55.00, for a total transaction of $275,000.00. Following the transaction, the general counsel now directly owns 9,567 shares of the company’s stock, valued at $526,185. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 28,650 shares of Spark Therapeutics stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $80.01, for a total transaction of $2,292,286.50. Following the transaction, the chief executive officer now directly owns 258,650 shares in the company, valued at $20,694,586.50. The disclosure for this sale can be found here. Insiders have sold 339,310 shares of company stock worth $23,787,138 over the last ninety days. 7.30% of the stock is owned by insiders.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

What are top analysts saying about Spark Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spark Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit